IBDEI0G6 ; ; 12-MAY-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 12, 2016
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,16205,0)
 ;;=C10.9^^64^780^8
 ;;^UTILITY(U,$J,358.3,16205,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16205,1,3,0)
 ;;=3^Malig Neop Oropharynx,Unspec
 ;;^UTILITY(U,$J,358.3,16205,1,4,0)
 ;;=4^C10.9
 ;;^UTILITY(U,$J,358.3,16205,2)
 ;;=^5000909
 ;;^UTILITY(U,$J,358.3,16206,0)
 ;;=C38.4^^64^780^9
 ;;^UTILITY(U,$J,358.3,16206,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16206,1,3,0)
 ;;=3^Malig Neop Pleura
 ;;^UTILITY(U,$J,358.3,16206,1,4,0)
 ;;=4^C38.4
 ;;^UTILITY(U,$J,358.3,16206,2)
 ;;=^267140
 ;;^UTILITY(U,$J,358.3,16207,0)
 ;;=C45.0^^64^780^15
 ;;^UTILITY(U,$J,358.3,16207,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16207,1,3,0)
 ;;=3^Mesothelioma of Pleura
 ;;^UTILITY(U,$J,358.3,16207,1,4,0)
 ;;=4^C45.0
 ;;^UTILITY(U,$J,358.3,16207,2)
 ;;=^5001095
 ;;^UTILITY(U,$J,358.3,16208,0)
 ;;=C73.^^64^780^11
 ;;^UTILITY(U,$J,358.3,16208,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16208,1,3,0)
 ;;=3^Malig Neop Thyroid Gland
 ;;^UTILITY(U,$J,358.3,16208,1,4,0)
 ;;=4^C73.
 ;;^UTILITY(U,$J,358.3,16208,2)
 ;;=^267296
 ;;^UTILITY(U,$J,358.3,16209,0)
 ;;=C02.9^^64^780^13
 ;;^UTILITY(U,$J,358.3,16209,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16209,1,3,0)
 ;;=3^Malig Neop Tongue,Unspec
 ;;^UTILITY(U,$J,358.3,16209,1,4,0)
 ;;=4^C02.9
 ;;^UTILITY(U,$J,358.3,16209,2)
 ;;=^5000891
 ;;^UTILITY(U,$J,358.3,16210,0)
 ;;=C33.^^64^780^14
 ;;^UTILITY(U,$J,358.3,16210,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16210,1,3,0)
 ;;=3^Malig Neop Trachea
 ;;^UTILITY(U,$J,358.3,16210,1,4,0)
 ;;=4^C33.
 ;;^UTILITY(U,$J,358.3,16210,2)
 ;;=^267135
 ;;^UTILITY(U,$J,358.3,16211,0)
 ;;=D70.9^^64^781^3
 ;;^UTILITY(U,$J,358.3,16211,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16211,1,3,0)
 ;;=3^Neutropenia,Unspec
 ;;^UTILITY(U,$J,358.3,16211,1,4,0)
 ;;=4^D70.9
 ;;^UTILITY(U,$J,358.3,16211,2)
 ;;=^334186
 ;;^UTILITY(U,$J,358.3,16212,0)
 ;;=D57.1^^64^781^4
 ;;^UTILITY(U,$J,358.3,16212,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16212,1,3,0)
 ;;=3^Sickle-Cell Disease w/o Crisis
 ;;^UTILITY(U,$J,358.3,16212,1,4,0)
 ;;=4^D57.1
 ;;^UTILITY(U,$J,358.3,16212,2)
 ;;=^5002309
 ;;^UTILITY(U,$J,358.3,16213,0)
 ;;=D57.00^^64^781^1
 ;;^UTILITY(U,$J,358.3,16213,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16213,1,3,0)
 ;;=3^Hb-SS Disease w/ Crisis,Unspec
 ;;^UTILITY(U,$J,358.3,16213,1,4,0)
 ;;=4^D57.00
 ;;^UTILITY(U,$J,358.3,16213,2)
 ;;=^5002306
 ;;^UTILITY(U,$J,358.3,16214,0)
 ;;=D73.1^^64^781^2
 ;;^UTILITY(U,$J,358.3,16214,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16214,1,3,0)
 ;;=3^Hypersplenism
 ;;^UTILITY(U,$J,358.3,16214,1,4,0)
 ;;=4^D73.1
 ;;^UTILITY(U,$J,358.3,16214,2)
 ;;=^60330
 ;;^UTILITY(U,$J,358.3,16215,0)
 ;;=D57.819^^64^781^5
 ;;^UTILITY(U,$J,358.3,16215,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16215,1,3,0)
 ;;=3^Sickle-Cell Disorders w/ Crisis,Unspec
 ;;^UTILITY(U,$J,358.3,16215,1,4,0)
 ;;=4^D57.819
 ;;^UTILITY(U,$J,358.3,16215,2)
 ;;=^5002320
 ;;^UTILITY(U,$J,358.3,16216,0)
 ;;=D57.3^^64^781^7
 ;;^UTILITY(U,$J,358.3,16216,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16216,1,3,0)
 ;;=3^Sickle-Cell Trait
 ;;^UTILITY(U,$J,358.3,16216,1,4,0)
 ;;=4^D57.3
 ;;^UTILITY(U,$J,358.3,16216,2)
 ;;=^5002313
 ;;^UTILITY(U,$J,358.3,16217,0)
 ;;=D57.20^^64^781^8
 ;;^UTILITY(U,$J,358.3,16217,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16217,1,3,0)
 ;;=3^Sickle-Cell/Hb-C Disease w/o Crisis
 ;;^UTILITY(U,$J,358.3,16217,1,4,0)
 ;;=4^D57.20
 ;;^UTILITY(U,$J,358.3,16217,2)
 ;;=^330080
 ;;^UTILITY(U,$J,358.3,16218,0)
 ;;=D56.8^^64^781^9
 ;;^UTILITY(U,$J,358.3,16218,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16218,1,3,0)
 ;;=3^Thalassemias
 ;;^UTILITY(U,$J,358.3,16218,1,4,0)
 ;;=4^D56.8
 ;;^UTILITY(U,$J,358.3,16218,2)
 ;;=^5002305
 ;;^UTILITY(U,$J,358.3,16219,0)
 ;;=D57.40^^64^781^6
 ;;^UTILITY(U,$J,358.3,16219,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16219,1,3,0)
 ;;=3^Sickle-Cell Thalassemia w/o Crisis
 ;;^UTILITY(U,$J,358.3,16219,1,4,0)
 ;;=4^D57.40
 ;;^UTILITY(U,$J,358.3,16219,2)
 ;;=^329908
 ;;^UTILITY(U,$J,358.3,16220,0)
 ;;=C91.01^^64^782^20
 ;;^UTILITY(U,$J,358.3,16220,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16220,1,3,0)
 ;;=3^Lymphoblastic Leukemia,Acute,In Remission
 ;;^UTILITY(U,$J,358.3,16220,1,4,0)
 ;;=4^C91.01
 ;;^UTILITY(U,$J,358.3,16220,2)
 ;;=^5001763
 ;;^UTILITY(U,$J,358.3,16221,0)
 ;;=C91.00^^64^782^21
 ;;^UTILITY(U,$J,358.3,16221,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16221,1,3,0)
 ;;=3^Lymphoblastic Leukemia,Acute,Not in Remission
 ;;^UTILITY(U,$J,358.3,16221,1,4,0)
 ;;=4^C91.00
 ;;^UTILITY(U,$J,358.3,16221,2)
 ;;=^5001762
 ;;^UTILITY(U,$J,358.3,16222,0)
 ;;=C92.41^^64^782^41
 ;;^UTILITY(U,$J,358.3,16222,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16222,1,3,0)
 ;;=3^Promyleocytic Leukemia,Acute,In Remission
 ;;^UTILITY(U,$J,358.3,16222,1,4,0)
 ;;=4^C92.41
 ;;^UTILITY(U,$J,358.3,16222,2)
 ;;=^5001802
 ;;^UTILITY(U,$J,358.3,16223,0)
 ;;=C92.01^^64^782^32
 ;;^UTILITY(U,$J,358.3,16223,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16223,1,3,0)
 ;;=3^Myeloblastic Leukemia,Acute,In Remission
 ;;^UTILITY(U,$J,358.3,16223,1,4,0)
 ;;=4^C92.01
 ;;^UTILITY(U,$J,358.3,16223,2)
 ;;=^5001790
 ;;^UTILITY(U,$J,358.3,16224,0)
 ;;=C92.51^^64^782^35
 ;;^UTILITY(U,$J,358.3,16224,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16224,1,3,0)
 ;;=3^Myelomonocytic Leukemia,Acute,In Remission
 ;;^UTILITY(U,$J,358.3,16224,1,4,0)
 ;;=4^C92.51
 ;;^UTILITY(U,$J,358.3,16224,2)
 ;;=^5001805
 ;;^UTILITY(U,$J,358.3,16225,0)
 ;;=C91.11^^64^782^24
 ;;^UTILITY(U,$J,358.3,16225,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16225,1,3,0)
 ;;=3^Lymphocytic B-Cell Type Leukemia,Chr,In Remission
 ;;^UTILITY(U,$J,358.3,16225,1,4,0)
 ;;=4^C91.11
 ;;^UTILITY(U,$J,358.3,16225,2)
 ;;=^5001766
 ;;^UTILITY(U,$J,358.3,16226,0)
 ;;=C91.10^^64^782^25
 ;;^UTILITY(U,$J,358.3,16226,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16226,1,3,0)
 ;;=3^Lymphocytic B-Cell Type Leukemia,Chr,Not in Remission
 ;;^UTILITY(U,$J,358.3,16226,1,4,0)
 ;;=4^C91.10
 ;;^UTILITY(U,$J,358.3,16226,2)
 ;;=^5001765
 ;;^UTILITY(U,$J,358.3,16227,0)
 ;;=C92.11^^64^782^33
 ;;^UTILITY(U,$J,358.3,16227,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16227,1,3,0)
 ;;=3^Myeloid Leukemia,BCR/ABL-Positive,Chr,In Remission
 ;;^UTILITY(U,$J,358.3,16227,1,4,0)
 ;;=4^C92.11
 ;;^UTILITY(U,$J,358.3,16227,2)
 ;;=^5001793
 ;;^UTILITY(U,$J,358.3,16228,0)
 ;;=C92.10^^64^782^34
 ;;^UTILITY(U,$J,358.3,16228,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16228,1,3,0)
 ;;=3^Myeloid Leukemia,BCR/ABL-Positive,Chr,Not in Remission
 ;;^UTILITY(U,$J,358.3,16228,1,4,0)
 ;;=4^C92.10
 ;;^UTILITY(U,$J,358.3,16228,2)
 ;;=^5001792
 ;;^UTILITY(U,$J,358.3,16229,0)
 ;;=C91.40^^64^782^7
 ;;^UTILITY(U,$J,358.3,16229,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16229,1,3,0)
 ;;=3^Hairy Cell Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,16229,1,4,0)
 ;;=4^C91.40
 ;;^UTILITY(U,$J,358.3,16229,2)
 ;;=^5001771
 ;;^UTILITY(U,$J,358.3,16230,0)
 ;;=C81.90^^64^782^19
 ;;^UTILITY(U,$J,358.3,16230,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16230,1,3,0)
 ;;=3^Hodgkin Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,16230,1,4,0)
 ;;=4^C81.90
 ;;^UTILITY(U,$J,358.3,16230,2)
 ;;=^5001451
 ;;^UTILITY(U,$J,358.3,16231,0)
 ;;=C81.99^^64^782^26
 ;;^UTILITY(U,$J,358.3,16231,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16231,1,3,0)
 ;;=3^Lymphoma,Extrnod & Solid Org Sites,Unspec
 ;;^UTILITY(U,$J,358.3,16231,1,4,0)
 ;;=4^C81.99
 ;;^UTILITY(U,$J,358.3,16231,2)
 ;;=^5001460
 ;;^UTILITY(U,$J,358.3,16232,0)
 ;;=C81.00^^64^782^16
 ;;^UTILITY(U,$J,358.3,16232,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16232,1,3,0)
 ;;=3^Hodgkin Lymphoma,Nodular Lymphocyte,Unspec Site
 ;;^UTILITY(U,$J,358.3,16232,1,4,0)
 ;;=4^C81.00
 ;;^UTILITY(U,$J,358.3,16232,2)
 ;;=^5001391
 ;;^UTILITY(U,$J,358.3,16233,0)
 ;;=C81.09^^64^782^15
